Seek Returns

ASND vs. VTRS: Ascendis Pharma vs. Viatris Stock Comparison

How do Ascendis Pharma (ASND) and Viatris (VTRS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Ascendis Pharma (ASND) and Viatris (VTRS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ASND is classified in Biotechnology while VTRS is classified in Pharmaceuticals.

Company profile comparison for Ascendis Pharma (ASND) and Viatris (VTRS)
Profile ItemASNDVTRS
NameAscendis Pharma A/SViatris Inc.
Country/RegionDenmarkUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyPharmaceuticals
GICS Sub-IndustryBiotechnologyPharmaceuticals
Market Capitalization16.90 billion USD22.83 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateJanuary 28, 2015March 17, 1980
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

ASND
VTRS
GSPC
Loading price history…
Ascendis Pharma (ASND) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Ascendis Pharma (ASND) and Viatris (VTRS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Ascendis Pharma (ASND) and Viatris (VTRS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Ascendis Pharma (ASND) and Viatris (VTRS)
MetricASNDVTRS
Total Return (1Y)29.46%108.98%
Total Return (3Y, Annualized)40.62%36.75%
Total Return (5Y, Annualized)10.03%11.59%

Risk Profile

Drawdown History

ASND
VTRS
GSPC
Loading price history…
Ascendis Pharma (ASND) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Ascendis Pharma (ASND) and Viatris (VTRS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Ascendis Pharma (ASND) and Viatris (VTRS)
MetricASNDVTRS
Volatility (1Y, Annualized)38.62%32.53%
Beta (5Y)0.380.86
Max Drawdown (5Y)-55.93%-45.69%
Avg. Volume (3M)698.39K8.87M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
ASND and VTRS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Ascendis Pharma (ASND) and Viatris (VTRS)
MetricASNDVTRS
Sharpe Ratio (1Y)0.653.22
Sortino Ratio (1Y)0.995.63

Profitability

ROE (TTM)

Viatris (VTRS) reports a negative ROE of -4.21%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Ascendis Pharma (ASND) reports 118.78%, ranking against industry peers normally.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

118.78%

ASND
118.78%
Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.21%

Max
109.18%
Q3
6.23%
VTRS
-4.21%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Ascendis Pharma (ASND) vs. Viatris (VTRS): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Viatris (VTRS) reports a negative net margin of -4.13%, usually indicating a net loss over the period. Meanwhile Ascendis Pharma (ASND) reports 70.85%, ranking against industry peers normally.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

70.85%

ASND
70.85%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.13%

Max
18.05%
Q3
4.78%
Median
0.00%
VTRS
-4.13%
Q1
-4.14%
Min
-17.05%
Loading chart…
Ascendis Pharma (ASND) vs. Viatris (VTRS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Ascendis Pharma (ASND) at 64.98% operates in the top operating margin quartile, ahead of Viatris (VTRS) at 13.85%, which runs around its industry’s norm.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

64.98%

Max
83.12%
ASND
64.98%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.85%

Max
83.12%
Q3
14.77%
VTRS
13.85%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Ascendis Pharma (ASND) vs. Viatris (VTRS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Ascendis Pharma (ASND) and Viatris (VTRS)
MetricASNDVTRS
ROE (TTM)118.78%-4.21%
ROA (TTM)9.58%2.91%
Net Margin (TTM)70.85%-4.13%
Operating Margin (TTM)64.98%13.85%
Gross Margin (TTM)91.30%41.13%

Growth

Revenue Growth

Ascendis Pharma (ASND) at 98.03% sits in the top revenue growth quartile, while Viatris (VTRS) at -2.98% is in the bottom quartile, showing a clear gap in revenue momentum.

Loading chart…
Ascendis Pharma (ASND) vs. Viatris (VTRS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither Ascendis Pharma (ASND) nor Viatris (VTRS) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Growth metrics for Ascendis Pharma (ASND) and Viatris (VTRS)
MetricASNDVTRS
Revenue Growth (YoY)98.03%-2.98%
Revenue Growth (3Y CAGR)141.43%-4.20%
EPS Growth (YoY)----
EPS Growth (3Y CAGR)----

Financial Strength

Current Ratio (MRQ)

Ascendis Pharma (ASND) at 2.99 keeps current ratio within its industry’s typical mid-range, while Viatris (VTRS) at 1.55 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for VTRS.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.99

Max
25.13
Q3
12.13
Median
5.52
ASND
2.99
Q1
2.47
Min
0.10

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
VTRS
1.55
Min
0.10
Loading chart…
Ascendis Pharma (ASND) vs. Viatris (VTRS): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Ascendis Pharma (ASND) at 0.31 carries an industry-typical debt-to-equity mix, while Viatris (VTRS) at 0.99 uses more debt funding than most peers.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.31

Max
1.42
Q3
0.65
ASND
0.31
Median
0.15
Q1
0.02
Min
0.00

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.99

Max
1.42
VTRS
0.99
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Ascendis Pharma (ASND) vs. Viatris (VTRS): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Ascendis Pharma (ASND) and Viatris (VTRS)
MetricASNDVTRS
Current Ratio (MRQ)2.991.55
Debt / Equity (MRQ)0.310.99
Net Debt / EBITDA-1.372.64

Dividends

Dividend Yield (TTM)

Ascendis Pharma (ASND) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Viatris (VTRS) reports a yield of 2.53%, ranking against industry peers normally.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ASND
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.53%

VTRS
2.53%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Ascendis Pharma (ASND) vs. Viatris (VTRS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Viatris (VTRS) reports payout ratio above 100% at 960.00%, meaning dividends exceeded current-period earnings; Ascendis Pharma (ASND) pays no dividend (payout 0.00%).

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ASND
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

960.00%

VTRS
960.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Ascendis Pharma (ASND) vs. Viatris (VTRS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Ascendis Pharma (ASND) and Viatris (VTRS)
MetricASNDVTRS
Dividend Yield (TTM)0.00%2.53%
Dividend Payout Ratio (TTM)0.00%960.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Ascendis Pharma (ASND) trades at 19.68 times trailing earnings, ranked against its peers, while Viatris (VTRS) has no P/E ratio this period.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.68

Max
85.34
Q3
43.46
Median
26.69
ASND
19.68
Q1
13.30
Min
0.07

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
VTRS
--
Loading chart…
Ascendis Pharma (ASND) vs. Viatris (VTRS): VTRS does not report P/E ratio, so it has no value marker; ASND is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

Viatris (VTRS) at 1.55 sits in the cheaper P/S ratio quartile while Ascendis Pharma (ASND) at 16.14 prices around its industry’s middle — VTRS costs less per dollar of sales, though read it alongside growth and margins.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.14

Max
58.18
Q3
25.77
ASND
16.14
Median
7.30
Q1
3.01
Min
0.01

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
VTRS
1.55
Min
0.01
Loading chart…
Ascendis Pharma (ASND) vs. Viatris (VTRS): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Viatris (VTRS) at 1.67 looks cheap against book in the lower P/B ratio quartile, while Ascendis Pharma (ASND) at 10.45 carries a premium in the upper quartile — a clear price-to-book gap.

ASND

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.45

Max
13.53
ASND
10.45
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.67

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
VTRS
1.67
Min
-5.59
Loading chart…
Ascendis Pharma (ASND) vs. Viatris (VTRS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Ascendis Pharma (ASND) and Viatris (VTRS)
MetricASNDVTRS
P/E Ratio (TTM)19.68--
P/S Ratio (TTM)16.141.55
P/B Ratio (MRQ)10.451.67
Free Cash Flow Yield (TTM)0.08%13.84%